# Clarity Audit Report: $100M Robotics Capital Allocation Plan

**Auditor:** Independent Clarity Reviewer
**Date:** February 16, 2026
**Document Reviewed:** investment-plan.md
**Audit Scope:** Accessibility to sophisticated non-specialist investors

---

## Overall Assessment: **PASS WITH RESERVATIONS**

The document is substantially clear and actionable, with strong structural logic and well-defined reasoning. However, it contains **15+ critical instances of unexplained jargon** that would impede comprehension for non-specialist investors. The document assumes robotics domain knowledge in several key sections.

**Recommendation:** Minor revisions required before distribution to non-specialist LPs or investment committees lacking robotics expertise.

---

## Detailed Findings

### 1. Would a sophisticated but non-specialist investor understand this?

**Rating: 7/10 (Good, but not excellent)**

**Strengths:**
- The strategic logic is crystal clear: diversify across proven categories, reserve judgment on AI-first thesis, avoid overvalued humanoids
- The tier structure (48%/35%/17%) communicates conviction levels effectively
- Risk acknowledgments ("What This Plan Gets Wrong") demonstrate intellectual honesty
- Alternative strategies section allows reader to calibrate their own risk tolerance

**Weaknesses:**
- Several technical concepts are assumed rather than explained (e.g., "sim-to-real transfer," "cross-embodiment transfer," "synthetic data generation")
- The medical robotics section uses clinical terminology without definition
- Manufacturing concepts (TCO, integrator dynamics) may be unclear to pure financial investors

---

### 2. Is jargon defined?

**Rating: 4/10 (Critical gaps)**

**UNDEFINED JARGON REQUIRING EXPLANATION:**

#### Financial/Business Terms:
- **EBITDA** (line 48) - Never expanded or defined
- **ITAR** (lines 125, 129) - Mentioned 3 times, never explained
- **510(k)** (line 40) - Critical regulatory pathway, not defined
- **CAGR** - Not used, but TCO is used without definition
- **TCO** (Total Cost of Ownership) - Used multiple times (lines 54, 106, 248), never defined
- **Razor-and-blade model** (lines 30, 33) - Business model jargon, not explained

#### Technical/Robotics Terms:
- **Sim-to-real transfer** (line 106) - Critical AI concept, never explained
- **Cross-embodiment transfer** (line 104) - Advanced ML concept with no context
- **Synthetic data generation** (line 83) - Technical concept, meaning unclear
- **Teleoperation** (line 83) - Robotics term, not defined
- **Cobot** (line 162) - Robotics jargon (collaborative robot), unexplained
- **ISR** (line 132) - Military acronym, undefined
- **EOD** (line 132) - Military acronym, undefined
- **Harmonic drive** (line 168) - Precision engineering component, not explained

#### Medical Terms:
- **Gross margins** - Used extensively but context suggests not all readers understand margin economics
- **Reimbursement codes** (line 35) - Healthcare financing concept, not explained
- **De novo device** (line 38) - FDA regulatory term, undefined

**PROPERLY HANDLED ACRONYMS:**
- FDA - First use includes context (line 29), though not fully expanded
- ML - Used informally, meaning clear from context
- CFIUS (line 242) - Not expanded, but geopolitical context makes purpose clear enough

---

### 3. Are assumptions stated clearly?

**Rating: 9/10 (Excellent)**

**Clear assumptions:**
- "Generalist allocator with no specific edge" (line 10) - Explicitly stated
- 10-year time horizon - Clear throughout
- Target returns at each tier - Explicitly stated with ranges
- Deployment schedule - Year-by-year breakdown provided
- "Robotics transition is real" - Core thesis stated upfront
- Market mispricing thesis - Clear articulation of why obvious/boring winners are better bets

**Strong assumption documentation:**
- Each position includes "Why" and "Why not more" sections
- Falsifiable claims (e.g., David Chen's 2029 test on line 106)
- Explicit acknowledgment of uncertainties (lines 269-280)

**Minor gap:**
- Currency assumption (USD implied but not stated)
- Geographic base of deploying capital not specified (US-based? Singapore? Matters for tax/access)

---

### 4. Does the brief give enough context for decision-making?

**Rating: 8/10 (Very Good)**

**Actionable elements:**
- Entry criteria specified for most positions (e.g., lines 40-41 for medical, 57-61 for integrators)
- Red flags clearly stated ("What to avoid" sections)
- Year-by-year deployment schedule (lines 219-228)
- Decision triggers with monitoring criteria (lines 234-254)
- Team structure recommendations (lines 256-263)

**Enables concrete actions:**
- Reader can identify investable companies using stated criteria
- Deal team can screen opportunities against explicit thresholds
- Operating partners can assess technical viability using provided frameworks

**Minor weaknesses:**
- "2-3 positions" or "3-4 positions" - No guidance on concentration within categories
- No discussion of legal structure (fund? direct holding? SPV per category?)
- Portfolio construction details missing (rebalancing triggers, liquidity management)

---

### 5. Is the structure logical and navigable?

**Rating: 10/10 (Excellent)**

**Outstanding structural elements:**
- Three-tier classification by conviction level
- Consistent format within each position (What/Why/Entry Criteria/Target Return)
- Executive summary provides roadmap
- Table of deployment schedule (lines 221-228)
- "What This Plan Gets Wrong" section prevents overconfidence
- "If You Choose Differently" provides alternative paths

**Navigation aids:**
- Clear hierarchy (Tier → Position → Subsection)
- Percentage allocations in section headers
- Year markers for temporal sequencing
- Named attribution to specific frameworks adds credibility and traceability

---

### 6. Are acronyms expanded on first use?

**Rating: 3/10 (Poor)**

**Failures:**
- EBITDA - Never expanded (first use line 48)
- ITAR - Never expanded (first use line 125)
- 510(k) - Never expanded (first use line 40)
- TCO - Never expanded (multiple uses)
- ISR - Never expanded (line 132)
- EOD - Never expanded (line 132)
- ML - Used informally without expansion (context makes it clear, but still violates convention)

**Successes:**
- FDA - Implicitly clear from context, though not formally expanded
- SPACs - Used once (line 209), meaning reasonably inferable

**This is the document's most significant accessibility failure.** Standard practice requires expansion on first use, with acronym in parentheses.

---

### 7. Could someone act on these recommendations?

**Rating: 8/10 (Very Good)**

**Highly actionable elements:**

**Integrator acquisitions (Position #2):**
- Clear acquisition criteria: $5M+ EBITDA, 70%+ retention, specific sectors
- Valuation guidance: 5-8x EBITDA entry, 12-14x exit target
- Five-step operational playbook provided
- Leverage strategy specified ($30-50M debt against recurring revenue)

**Medical robotics (Position #1):**
- Specific screening criteria: 510(k) filed, 2+ clinical studies, $10M+ revenue, 55%+ margins
- Named comparable companies (Intuitive Surgical, Stryker Mako) for benchmarking
- Clear red flags (pre-clinical, consumer health)

**Data/simulation (Position #3):**
- Three customer minimum
- Team composition requirements
- Technical differentiation requirement vs. open source

**Less actionable elements:**

**AI foundation models (Position #4):**
- "Lower TCO than purpose-built systems" - How measured? What's the threshold?
- "Manipulation-focused" - Needs clearer definition
- "$5B valuation / $50M revenue" threshold is clear, but what about intermediate cases?

**Boring robotics (Position #6):**
- "$45/hr wage threshold" is concrete
- "Workers genuinely unavailable" is subjective - needs clearer metrics
- "Positive unit economics at current volumes" - No guidance on how to verify this

**Overall:** A competent deal team could begin sourcing and evaluating opportunities immediately using this document, though some categories would require clarifying conversations with the allocator.

---

## Critical Gaps in Accessibility

### 1. **Regulatory Knowledge Assumed**
Lines 29-38 assume reader understands:
- FDA clearance pathways (510(k) vs. de novo vs. PMA)
- Clinical evidence standards
- Reimbursement code systems
- The economic implications of regulatory moats

**Fix:** Add 2-3 sentence primer on FDA pathways and why they create moats.

### 2. **AI/ML Technical Concepts Assumed**
Lines 100-108 assume reader understands:
- Foundation models
- Sim-to-real transfer
- Cross-embodiment learning
- Training data flywheels
- The "Bitter Lesson" (referenced but not explained)

**Fix:** Add footnote or brief explanation when first introducing each concept.

### 3. **Manufacturing/Operations Concepts Assumed**
Lines 48-69 assume reader understands:
- What an integrator does
- TCO breakdown in robotics deployment
- The economics of service vs. hardware revenue
- Why integration is 25% of TCO (asserted without explanation)

**Fix:** Add one paragraph explaining the robotics value chain (manufacturer → integrator → end user).

### 4. **Defense/Procurement Jargon**
Lines 122-136 assume reader understands:
- ITAR restrictions and implications
- Defense procurement cycle mechanics
- Cost-plus contracting
- DARPA funding model
- Why software-defined and hardware-agnostic matters in defense

**Fix:** Expand ITAR acronym, add 1-2 sentences on why it creates a moat.

---

## Specific Recommendations for Revision

### High Priority (Impede Understanding):

1. **Add glossary section** at the end covering:
   - EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)
   - ITAR (International Traffic in Arms Regulations)
   - 510(k) (FDA clearance pathway for medical devices)
   - TCO (Total Cost of Ownership)
   - Cobot (Collaborative robot)
   - ISR (Intelligence, Surveillance, Reconnaissance)
   - EOD (Explosive Ordnance Disposal)

2. **Expand acronyms on first use** throughout document

3. **Add 2-3 sentence explainer** for:
   - Foundation models and why they matter (before line 100)
   - The robotics value chain (manufacturer/integrator/end-user) (before line 48)
   - FDA regulatory pathways and why they create moats (before line 29)

### Medium Priority (Improve Accessibility):

4. **Define "razor-and-blade"** business model on first use (line 30)

5. **Explain "Bitter Lesson"** reference or remove (line 104) - this is a reference to Richard Sutton's famous essay, but likely unknown to non-AI specialists

6. **Clarify "sim-to-real transfer"** - add parenthetical: "(training robots in simulation, then deploying to physical world)"

7. **Add brief context for DARPA** (line 126) - not all investors know it's the US defense research agency

### Low Priority (Polish):

8. **Specify currency** (USD) in opening paragraphs

9. **Add legal/tax structure consideration** (even if just to note "structure TBD based on allocator's domicile")

10. **Expand on concentration guidance** within categories (2-3 positions could be 50/50 or 70/20/10 - does it matter?)

---

## What the Document Does Exceptionally Well

1. **Intellectual honesty** - The "What This Plan Gets Wrong" section (lines 267-280) is rare and valuable

2. **Attribution and traceability** - Named frameworks (Asha's thesis, Sandra's playbook, Felix's second-order logic) allow reader to evaluate source credibility

3. **Decision triggers** - The Year 2-3 decision points (lines 234-250) with specific monitoring criteria are unusually concrete

4. **Alternative paths** - The "If You Choose Differently" section (lines 284-292) shows the allocator considered other strategies seriously

5. **Risk calibration** - Each position includes "Why not more" reasoning, which is more valuable than typical investment memos that only argue for the position

6. **Base rate honesty** - Explicitly stating Sandra's 33% hit rate (line 278) rather than hiding it is commendable

---

## Final Verdict

**PASS WITH MINOR REVISIONS REQUIRED**

This is a strong investment plan that survived adversarial review and demonstrates sophisticated thinking. The strategic logic is sound, the reasoning is traceable, and the structure is excellent.

**However, it is currently accessible to ~70% of sophisticated generalist investors.** The remaining 30% would struggle with unexplained jargon in medical devices, defense procurement, AI/ML concepts, and manufacturing operations.

**Required changes to reach 95% accessibility:**
1. Add glossary (15 minutes)
2. Expand 8-10 critical acronyms on first use (15 minutes)
3. Add 3 brief explainer paragraphs for FDA pathways, robotics value chain, and foundation models (30 minutes)

**Estimated revision time: 60 minutes**

Without these changes, the document risks:
- Investment committee members focusing on jargon instead of substance
- Misunderstanding of key positions (especially medical robotics and AI)
- Questions about whether the author understands their audience

With these changes, the document would be excellent: clear, actionable, intellectually honest, and accessible to any sophisticated allocator regardless of prior robotics knowledge.

---

## Audit Methodology

This audit was performed by:
1. Reading the document as a first-time reader with no prior context
2. Flagging every acronym, technical term, or concept that required domain knowledge
3. Evaluating whether a sophisticated investor from private equity, venture capital, or asset management could act on recommendations
4. Assessing structure, navigation, and decision-support quality
5. Comparing against best practices for investment memos and LP communications

The auditor had no involvement in document creation and evaluated solely based on the deliverable content.
